Stock FAB FUSION ANTIBODIES PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Fusion Antibodies plc

Equities

FAB

GB00BDQZGK16

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:06 2024-04-30 am EDT 		5-day change 1st Jan Change
3.225 GBX -9.15% Intraday chart for Fusion Antibodies plc -15.13% -24.12%
Apr. 15 Fusion Antibodies inks commercial contract for OptiPhage library AN
Apr. 15 Fusion Antibodies Secures Contract to Set Up OptiPhage Library MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Capitalization 1 6.296 20.99 40.21 15.61 10.02 3.385
Enterprise Value (EV) 1 6.296 19.83 40.21 15.61 10.02 3.385
P/E ratio -5 x -29.7 x -13.8 x -13 x -3.85 x -1.27 x
Yield - - - - - -
Capitalization / Revenue 2.89 x 5.39 x - - 3.45 x 2.94 x
EV / Revenue 2.89 x 5.39 x - - 3.45 x 2.94 x
EV / EBITDA -5.72 x -47.8 x - - -4.03 x -2.3 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 22,091 22,091 25,610 26,015 26,015 95,366
Reference price 2 0.2850 0.9500 1.570 0.6000 0.3850 0.0355
Announcement Date 7/2/19 8/19/20 8/10/21 8/23/22 9/29/23 -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Net sales 1 2.182 3.895 - - 2.901 1.15
EBITDA 1 -1.1 -0.439 - - -2.486 -1.474
EBIT 1 - -1.059 - - -2.858 -1.724
Operating Margin - -27.19% - - -98.52% -149.91%
Earnings before Tax (EBT) 1 - -1.073 - - -2.859 -1.736
Net income 1 - -0.697 -2.899 -1.2 -2.596 -1.59
Net margin - -17.89% - - -89.49% -138.26%
EPS 2 -0.0570 -0.0320 -0.1140 -0.0460 -0.1000 -0.0280
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/2/19 8/19/20 8/10/21 8/23/22 9/29/23 -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - 1.038 0.541 0.609
EBITDA 1 - -1.478 -1.231 -0.243
EBIT - - - -
Operating Margin - - - -
Earnings before Tax (EBT) - -1.597 -1.42 -
Net income -1.116 - - -
Net margin - - - -
EPS -0.0430 - - -
Dividend per Share - - - -
Announcement Date 12/5/22 9/29/23 12/4/23 -
1GBP in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024
Net Debt - - - - - -
Net Cash position - 1.16 - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 1.37 - - - 0.11 0.05
Capex / Sales 62.91% - - - 3.93% 4.35%
Announcement Date 7/2/19 8/19/20 8/10/21 8/23/22 9/29/23 -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
FUSION ANTIBODIES PLC Stock Fusion Antibodies plc
-24.12% 4.25M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.41% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+12.37% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.62% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.61% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.05% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.61% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.71% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FAB Stock
  4. Financials Fusion Antibodies plc